Due to the proven role of the rs72613567 insertion/deletion variant of HSD17B13, it could serve as a potential target for genetic-based precision medicine to treat NASH and liver fibrosis [15]. Here, HSD17B13 is linked to metabolic dysfunction-associated steatohepatitis.